Results 21 to 30 of about 23,189 (236)

Profiling Heparan Sulfate Proteoglycans in Ovarian Carcinoma [PDF]

The Scientific World Journal, 2005
: heparan sulfate, proteoglycans, syndecan, glypican, perlecan, ovarian carcinoma, angiogenesis, prognostic factors Heparan sulfate proteoglycans (HSPGs) are ubiquitously expressed cell surface and extracellular matrix (ECM) molecules consisting of a core protein covalently attached to the structurally complex glycosaminoglycan, heparan sulfate (HS ...
Andrew R. Clamp, Gordon C. Jayson
doaj   +4 more sources

Heparan Sulfate Proteoglycans: Key Mediators of Stem Cell Function [PDF]

Frontiers in Cell and Developmental Biology, 2020
Heparan sulfate proteoglycans (HSPGs) are an evolutionarily ancient subclass of glycoproteins with exquisite structural complexity. They are ubiquitously expressed across tissues and have been found to exert a multitude of effects on cell behavior and ...
Maanasa Ravikumar, Maanasa Ravikumar, Raymond Alexander Alfred Smith, Victor Nurcombe, Victor Nurcombe, Simon M. Cool, Simon M. Cool   +6 more
doaj   +2 more sources

Heparan sulfate proteoglycans present PCSK9 to the LDL receptor

Nature Communications, 2017
PCSK9 interacts with LDL receptor, causing its degradation, and consequently reduces the clearance of LDL. Here, Gustafsen et al. show that PCSK9 interacts with heparan sulfate proteoglycans and this binding favors LDLR degradation.
Camilla Gustafsen, Ditte Olsen, Joachim Vilstrup, Signe Lund, Anika Reinhardt, Niels Wellner, Torben Larsen, Christian B. F. Andersen, Kathrin Weyer, Jin-ping Li, Peter H. Seeberger, Søren Thirup, Peder Madsen, Simon Glerup   +13 more
doaj   +2 more sources

Infection and transmission of SARS-CoV-2 depend on heparan sulfate proteoglycans. [PDF]

EMBO J, 2021
The current pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and outbreaks of new variants highlight the need for preventive treatments. Here, we identified heparan sulfate proteoglycans as attachment receptors for SARS-CoV-
Bermejo-Jambrina M, Eder J, Kaptein TM, van Hamme JL, Helgers LC, Vlaming KE, Brouwer PJM, van Nuenen AC, Spaargaren M, de Bree GJ, Nijmeijer BM, Kootstra NA, van Gils MJ, Sanders RW, Geijtenbeek TBH.   +14 more
europepmc   +2 more sources

Apolipoprotein F is reduced in humans with steatosis and controls plasma triglyceride‐rich lipoprotein metabolism

Hepatology, EarlyView., 2022
Hepatic APOF transcript levels correlate inversely with plasma TG and hepatic steatosis in humans. ApoF expression in mice promotes VLDL‐TG production and lipoprotein remnant clearance in mice. Abstract Background NAFLD affects nearly 25% of the global population. Cardiovascular disease (CVD) is the most common cause of death among patients with NAFLD,
Audrey Deprince, Nathalie Hennuyer, Sander Kooijman, Amanda C. M. Pronk, Eric Baugé, Viktor Lienard, An Verrijken, Eveline Dirinck, Luisa Vonghia, Eloïse Woitrain, Niels J. Kloosterhuis, Eléonore Marez, Pauline Jacquemain, Justina C. Wolters, Fanny Lalloyer, Delphine Eberlé, Sandrine Quemener, Emmanuelle Vallez, Anne Tailleux, Mostafa Kouach, Jean‐Francois Goossens, Violeta Raverdy, Bruno Derudas, Jan Albert Kuivenhoven, Mikaël Croyal, Bart van de Sluis, Sven Francque, François Pattou, Patrick C. N. Rensen, Bart Staels, Joel T. Haas   +30 more
wiley   +1 more source

Adeno‐associated virus serotype 2 capsid variants for improved liver‐directed gene therapy

Hepatology, EarlyView., 2022
Abstract Background and Aims Current liver‐directed gene therapies look for adeno‐associated virus (AAV) vectors with improved efficacy. With this background, capsid engineering is explored. Whereas shuffled capsid library screenings have resulted in potent liver targeting variants with one first vector in human clinical trials, modifying natural ...
Nadja Meumann, Marti Cabanes‐Creus, Moritz Ertelt, Renina Gale Navarro, Julie Lucifora, Qinggong Yuan, Karin Nien‐Huber, Ahmed Abdelrahman, Xuan‐Khang Vu, Liang Zhang, Ann‐Christin Franke, Christian Schmithals, Albrecht Piiper, Annabelle Vogt, Maria Gonzalez‐Carmona, Jochen T. Frueh, Evelyn Ullrich, Philip Meuleman, Steven R. Talbot, Margarete Odenthal, Michael Ott, Erhard Seifried, Clara T. Schoeder, Joachim Schwäble, Leszek Lisowski, Hildegard Büning   +25 more
wiley   +1 more source

Specific structural features of syndecans and heparan sulfate chains are needed for cell signaling [PDF]

Brazilian Journal of Medical and Biological Research, 2006
The syndecans, heparan sulfate proteoglycans, are abundant molecules associated with the cell surface and extracellular matrix and consist of a protein core to which heparan sulfate chains are covalently attached. Each of the syndecan core proteins has a
C.C. Lopes, C.P. Dietrich, H.B. Nader
doaj   +1 more source

Heparan sulfate proteoglycan-dependent neutrophil chemotaxis toward PR-39 cathelicidin

Journal of Inflammation, 2006
Cathelicidins are mammalian proteins containing a C-terminal cationic antimicrobial domain. Porcine PR-39 cathelicidin affects leukocyte biology.
Patsch Josef R, Ricevuti Giovanni, Ross Christopher R, Kaneider Nicole C, Mosheimer Birgit, Djanani Angela, Wiedermann Christian J   +6 more
doaj   +1 more source

Heparan Sulfate Proteoglycans Biosynthesis and Post Synthesis Mechanisms Combine Few Enzymes and Few Core Proteins to Generate Extensive Structural and Functional Diversity

Molecules, 2020
Glycosylation is a common and widespread post-translational modification that affects a large majority of proteins. Of these, a small minority, about 20, are specifically modified by the addition of heparan sulfate, a linear polysaccharide from the ...
Thibault Annaval, Rebekka Wild, Yoann Crétinon, Rabia Sadir, Romain R. Vivès, Hugues Lortat-Jacob   +5 more
doaj   +1 more source

Requirements for receptor engagement during infection by adenovirus complexed with blood coagulation factor X [PDF]

, 2010
Human adenoviruses from multiple species bind to coagulation factor X (FX), yet the importance of this interaction in adenovirus dissemination is unknown.
Angela C Bradshaw, Duffy, Margaret R., Andrew H. Baker, Lynda Coughlan, Coughlan Lynda, Baker Andrew H., van Rooijen, Nico, van Rooijen, N., Nicklin, Stuart A., Margaret R Duffy, Parker, A.L., Kahari, V.M., Alan L Parker, Kähäri Veli-Matti, Stuart A Nicklin, Nico van Rooijen, Andrew H Baker, Coughlan, L., Nicklin Stuart A., Coughlan, Lynda, Kahari, Veli-Matti, Duffy, M.R., Parker Alan L., Bradshaw Angela C., Parker, Alan L., Duffy Margaret R., Bradshaw, Angela C., Bradshaw, A.C., Rooijen, N. van, Veli-Matti Kähäri, Angela C. Bradshaw, Alan L. Parker, Margaret R. Duffy, Stuart A. Nicklin, Baker, Andrew H., Baker, A.H., Nicklin, S.A., van Rooijen Nico   +37 more
core   +1 more source